This content is protected against AI scraping.
Introduction
Breaking the DPIA cost stranglehold in life sciences. Life sciences organisations now face DPIAs that are slow, manual and expensive. Consequently, these assessments create a hidden tax on innovation and trial start‑up.
How manual DPIAs hold life sciences back
Regulatory complexity now grows faster than most teams can handle. In particular, life sciences sit under GDPR, national health laws and clinical rules. Additionally, AI, medical device and sector guidance all pile on more expectations. As a result, almost every new study or platform can trigger a DPIA. This happens due to large‑scale sensitive data, cross‑border transfers and AI analytics. However, many organisations still rely on document‑heavy DPIAs. They use static templates, email chains and scattered files. Therefore, each assessment becomes a bespoke craft project. This fragmented model causes duplication and weak oversight. It also makes consistent risk treatment across portfolios almost impossible. Furthermore, time and cost increase quickly. Manual DPIAs often take days or weeks per assessment. Stakeholders across countries add more delay. This leads to
- External DPIA work can cost tens of thousands per project. Internal man‑hours increase those costs even further.
- These delays create real business risk. In clinical trials, uncertainty over ownership slows approvals. Moreover, trial start‑up and site activation can slip by weeks.
- Indirect costs hit just as hard. Projects pause, resources are reallocated and revenues arrive later than planned.
Why the current model fails
Many life sciences companies still treat DPIAs as one‑off artefacts. They complete them trial by trial, not at the framework level. Thus, privacy by design never truly embeds in the organisation. The same vendors, data flows and safeguards are re‑analysed repeatedly. This repetition inflates cost and stretches timelines.
At the same time, there is a talent bottleneck. A few privacy experts carry nearly all DPIA responsibility. Consequently, these experts become single points of failure. Business and study teams view DPIAs as a black box. Therefore, they often resist early engagement and see privacy as a hurdle. Innovation cycles make the gap even wider. Life sciences move toward platform trials, real‑world data and AI‑driven models. Yet DPIAs still run as slow, linear projects. This mismatch turns DPIAs into a compliance tax. They appear late and block progress instead of enabling safe design.
The DPIA Factory: an industrialised model
The DPIA Factory replaces one‑off assessments with a repeatable engine. It focuses on portfolios instead of individual projects. First, it uses standard blueprints for recurring scenarios. These include global trials, central labs, biobanks and real‑world evidence. They also cover companion apps, AI decision‑support and CRO models. Each study then becomes a variant of a master pattern. Teams adjust parameters instead of starting from a blank page.
Second, the Factory maintains central risk logic. One curated library links risks and controls to global and local rules. It embeds safeguards for genetic, biometric and health data. Local teams can then adapt this shared logic. They document local differences instead of reinventing each DPIA.
Third, the model introduces smart automation. Structured workflows replace chaotic email threads. Inputs, reviews and approvals follow clear paths. Existing records feed new assessments automatically. System inventories, vendor reviews and prior DPIAs populate key fields. Therefore, teams avoid endless fact‑finding.
With this approach, DPIAs move from weeks to hours for standard cases. Costs drop through reduced expert effort and reusable analysis. Moreover, the experience improves for clinical and product teams. Guided questions replace opaque templates. Clear risk outputs replace dense legal paragraphs. DPIAs then shift earlier in the lifecycle. They become design partners, not last‑minute obstacles.
Formiti’s role: a clearer pathway
Life sciences organisations need partners who understand both regulation and operations. They need support across global trials, labs and data platforms. Formiti already supports clients under GDPR, PDPA and other privacy regimes. The team blends legal, technical and operational expertise into one service. By applying the DPIA Factory mindset, Formiti helps clients escape bespoke, manual DPIAs. Instead, organisations gain a structured, reusable and scalable DPIA capability. In doing so, Formiti is leading a clearer pathway for life sciences. It breaks the cost and delay stranglehold not by doing fewer DPIAs, but by doing them differently.